ReviewBrain pathology (Zurich, Switzerland)2010
Biomarkers for cognitive impairment in Parkinson disease.
Review in Brain pathology (Zurich, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Imaging Biomarkers of Cognitive Impairment in Sarcopenia: A Narrative Review.International journal of general medicine · 2026Review
- Predicting cognitive impairment in Parkinson's disease: a machine learning approach based on clinical and neuropsychological data.Frontiers in neurology · 2025Article
- Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson's Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique.International journal of molecular sciences · 2023Article
- Alpha-Synuclein and Cognitive Decline in Parkinson Disease.Life (Basel, Switzerland) · 2021Review
- Quantitative Electroencephalography as a Biomarker for Cognitive Dysfunction in Parkinson's Disease.Frontiers in aging neuroscience · 2021Article
- EEG Slowing and Axial Motor Impairment Are Independent Predictors of Cognitive Worsening in a Three-Year Cohort of Patients With Parkinson's Disease.Frontiers in aging neuroscience · 2020Article
- Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease.Frontiers in neurology · 2020Review
- Functional Magnetic Resonance Imaging Biomarkers Predicting Cognitive Progression in Parkinson Disease: Protocol for a Prospective Longitudinal Cohort Study.JMIR research protocols · 2019Article
- Predicting the Post-therapy Severity Level (UPDRS-III) of Patients With Parkinson's Disease After Drug Therapy by Using the Dynamic Connectivity Efficiency of fMRI.Frontiers in neurology · 2019Article
- In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.Brain : a journal of neurology · 2018Article
- Identification of NURR1 (Exon 4) and FOXA1 (Exon 3) Haplotypes Associated with mRNA Expression Levels in Peripheral Blood Lymphocytes of Parkinson's Patients in Small Indian Population.Parkinson's disease · 2017Article
- Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease.Laboratory investigation; a journal of technical methods and pathology · 2014Article
- Paraoxonase 1 in neurological disorders.Redox report : communications in free radical research · 2014Review
- Mild cognitive impairment in Parkinson disease: heterogenous mechanisms.Journal of neural transmission (Vienna, Austria : 1996) · 2013Review
- Acute exposure to the mitochondrial complex I toxin rotenone impairs synaptic long-term potentiation in rat hippocampal slices.CNS neuroscience & therapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cognitive impairment, including dementia, is commonly seen in those afflicted with Parkinson disease (PD), particularly at advanced disease stages. Pathologically, PD with dementia (PD-D) is most often associated with the presence of cortical Lewy bodies, as is the closely related dementia with Lewy bodies (DLB). Both PD-D and DLB are also frequently complicated by the presence of neurofibrillary tangles and amyloid plaques, features most often attributed to Alzheimer disease. Biomarkers are urgently needed to differentiate among these disease processes and predict dementia in PD as well as monitor responses of patients to new therapies. A few clinical assessments, along with structural and functional neuroimaging, have been utilized in the last few years with some success in this area. Additionally, a number of other strategies have been employed to identify biochemical/molecular biomarkers associated with cognitive impairment and dementia in PD, e.g. targeted analysis of candidate proteins known to be important to PD pathogenesis and progression in cerebrospinal fluid or blood. Finally, interesting results are emerging from preliminary studies with unbiased and high throughput genomic, proteomic and metabolomic techniques. The current findings and perspectives of applying these strategies and techniques are reviewed in this article, together with potential areas of advancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.